Price T Rowe Associates Inc Cytokinetics Inc Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,625,081 shares of CYTK stock, worth $115 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,625,081
Previous 3,164,945
17.06%
Holding current value
$115 Million
Previous $167 Million
26.11%
% of portfolio
0.01%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$644 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$523 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$472 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$346 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$271 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.13B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...